Purple Biotech Ltd.

Pre-Annual General Meeting Information • Oct 29, 2025

convening of meeting false

���� ����� ��"�	2 670
PURPLE BIOTECH LTD
Corporation no: 520031238	16080
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C460 ( Public )		Reported via MAGNA:	29/10/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-081163	Time of broadcast: 06:34 06:34

---

Immediate Report of MeetingWhether to enable voting via the Voting System YesExplanation: Enabling voting via the Voting System is optional for dual-listing companies (including companies incorporated in Israel). Using the Voting System requires the company by law to process all votings made through it.

The corporation hereby gives notice of: convening of meeting

The reference number for the most recent notification of a meeting is _________ which was called for the date _________

Reason for Postponement or Cancellation: _________	_________

Explanation: Please refer to the reference number of the most recent notification of the convening or deferral of the meeting

1. On the date: 21/10/2025it was decided on convening of meeting extraordinary meeting _________ ,that will be held on the day Monday on the date : 15/12/2025 time: 16:30

at address:	Oppenheimer Street, Science Park, Rehovot, Israel

For the Voting System's needs: The last date for voting in the voting system shall be up to 4 hours from the date of convening the meetingExplanation: If this field is empty the default is six hours.

2. Details of security in the Stock Exchange that entitles the holder thereof to participate in the meetingSecurity number 765016Security name ���� ����� ��"�Security type ShareExplanation: If a meeting concerning more than one security is required, a report on C460 will be made separately for every additional security. Reports that specify additional security numbers must be followed by an amending reportThe determining date for entitlement to participate and vote in the meeting: 03/11/2025

3. On the Agenda - Items/Decisions to be raised at the meeting11The item/decision and its particulars:To approve the grant of equity-based awards to Gil Efron, the Chief Executive Officer of the Company, in such amounts and with such terms and conditions as described in Proposal 1 of the Proxy Statement for the Meeting.

Enable Editing the item/decision and its particulars

Does this require disclosure of any ties or other features of the voting security holder? YesBy marking the �NO� box, you confirm that you do not have a �personal interest� (as defined in the Israeli Companies Law, 1999) in the approval of this proposal. If you cannot make such confirmation, please check the �YES� box.Note: Please pose Yes/No questions. The question will appear in the voting system alongside the decision that is on the agenda, and the voter will have the option of voting Yes or No, and may add additional information if the voter votes Yes. For example, this field may be used to add a question pertaining to issues that require a declaration of personal interest and details of the interest if any.

In the event of a meeting of bondholdersResolution pertaining to other interests _________Details of the other interests_________Note: Details of the other interest determine which declaration is included in the online voting system. Please pose Yes/No questions. The question will appear in the voting system alongside the decision that is on the agenda, and the voter will have the option of voting Yes or No, and may add additional information if the voter votes Yes.

Resolution to require holders to provide additional details _________List of additional details required of holders or the manner in which meetings are convened (in the event of a meeting convened under section 350 of the Companies Law 350):_________Note: This field determines which demand for additional details is included in the online voting system. Voters may add text in the field.

	No longer on the agenda

Items brought for one of the following: Voting

Majority required not a simpe majority	Special majority under the Israeli Companies Law, 1999.

Attachment of report of convening meeting: ea0262767016kpurpleEDGAR1_isa.pdf

4. AttachedYes wording of the voting letterNo position notificationPPBT_-_Voting_Slip_for_2025_EGM2_isa.pdf

No declaration of candidate to serve as director in corporation.No declaration of independent directorNo declaration of outside director_________

5. The place and the times at which it is possible to examine any proposed decision the wording of which was not presented in full in the specification of the agenda above4 Oppenheimer Street, Science Park, Rehovot, Israel, During regular business hours.

6. Link to the Voting System site: Voting System

Meeting Identifier: _________Note: 'Meeting Identifier' is the first report's reference number. In the first report this field is empty.

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 06/08/2024
Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: ir@purple-biotech.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: ����� ���� Position of Signatory in the reporting corporation: Name of Employer Company:
Address: Oppenheimer, Science Park 4 , ������ 7670104 Telephone: 052-8957963 Facsimile: 03-5097196 E-mail: drors@purple-biotech.com 2
Israel